Third quarter results show extent of decline, but Gilead promises good times ahead

27 October 2017

Californian biotech major Gilead Sciences (Nasdaq: GILD) has shed over 1% of its share price after the company released third quarter 2017 results showing a 13% decline in revenue.

Total revenue was $6.5 billion in 2017 compared to $7.5 billion in 2016. Net income was $2.7 billion, compared to $3.3 billion, following results showing a 13% decline in revenue. generally accepted accounting principles.

That translates to an earnings per share figure of $2.06, down from $2.49 for the same period in 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK